India Diabetes Care Market to Grow at CAGR of 7.94% During the Forecast Period

Rising geriatric population, unhealthy lifestyle, obesity, advancing technology and increasing cost of living to drive the diabetes care market in India.

According to recently released TechSci Research report “India Diabetes Care Market By Type of Product (Diabetes Drug and Diabetic Devices), By Diabetes Type (Type 1, Type 2 and Gestational Diabetes), By End-User (Hospital, Homeclinic, Homecare) By Region, Competition, Forecast & Opportunities, 2026.’’, India diabetes caremarket is forecast to grow at CAGR of 7.94% in value terms to reach USD2,408.39 million by FY2026. Increasing demand for diabetes care has been generated from the country’s rising diabetic population. Various diabetes care manufacturing giants have introduced continuous glucose monitoring devices specially for type 1 diabetes, hyperglycaemia, and gestational diabetes.

Browse 20 Figures spread through 70 Pages and an in-depth TOC on “India Diabetes Care Market“.

https://www.techsciresearch.com/report/india-diabetes-care-market/7253.html

With the growth of urbanization, adoption of an unhealthy lifestyle and spending capacity of consumers in India has led to an increase in the diabetic population, which is driving the diabetes care market across the country.

India diabetes care market is categorized into diabetes drug and diabetes devices. The drug diabetes care segment holds the major market share, followed by devices. The devices category is growing fast in value terms due to feasibility of use. the value share of device diabetes care is anticipated to reach 47.18% by FY2026, owing to the continuous launch of better and easy to handle devices and rising disposable incomes.

Novo Nordisk India Private Limited, Sanofi India Limited, Eli Lilly India Pvt. Ltd., Roche Diagnostics India Pvt Ltd., Abbott India Limited, Becton Dickinson Private Limited, Johnson & Johnson Private Limited, India Medtronic Pvt. Ltd., Ypsomed India Private Ltd. and Novartis India Ltd are some of the companies operating in the India diabetes care market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7253

Customers can also request for 10% free customization on this report.

“Diabetes care market in India includes several players, including a blend of large multi-nationals as well as small players forming a large unorganized market. Multinational companies such as Abbott India Limited, Sanofi India Limited, Eli Lilly India Pvt, Novo Nordisk India Private Limited, etc., have either set up their production facilities in India or implement contract manufacturing processes, to grab the opportunity of booming diabetes care market and increase of their product portfolio as per consumers drug requirements which is expected to drive the growth of organized sector in the coming years. Also, guidelines related to manufacturing and marketing of diabetes care as per Indian and International standards have been implemented which is primarily focused on the development of newer products, exploitation of technology and enhancement of distribution network. This is expected to give a boost in the country’s Diabetes Care market in the coming years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.  

“India Diabetes Care Market By Type of Product (Diabetes Drug and Diabetic Devices), By Diabetes Type (Type 1, Type 2 and Gestational Diabetes), By End-User (Hospital, Homeclinic, Homecare) By Region, Competition, Forecast & Opportunities, 2026” has evaluated the future growth potential of India diabetes care market and provided statistics and information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in India diabetes care market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]